EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 183 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $74,419 | -70.2% | 4,719 | -63.2% | 0.00% | – |
Q2 2023 | $249,492 | -97.2% | 12,834 | -96.0% | 0.00% | -100.0% |
Q1 2023 | $9,026,596 | +653.5% | 318,174 | +676.4% | 0.00% | – |
Q4 2022 | $1,197,905 | +27.6% | 40,982 | +15.3% | 0.00% | – |
Q3 2022 | $939,000 | +543.2% | 35,540 | +980.9% | 0.00% | – |
Q2 2022 | $146,000 | -32.1% | 3,288 | -24.6% | 0.00% | – |
Q1 2022 | $215,000 | -95.4% | 4,360 | -95.3% | 0.00% | – |
Q4 2021 | $4,721,000 | +32.6% | 92,692 | +45.2% | 0.00% | – |
Q3 2021 | $3,560,000 | +37.6% | 63,819 | +5.6% | 0.00% | – |
Q2 2021 | $2,588,000 | -5.4% | 60,443 | -7.7% | 0.00% | – |
Q1 2021 | $2,735,000 | -12.9% | 65,512 | -2.8% | 0.00% | – |
Q4 2020 | $3,140,000 | -35.7% | 67,428 | -41.4% | 0.00% | -100.0% |
Q3 2020 | $4,887,000 | +38.7% | 115,062 | +56.6% | 0.00% | 0.0% |
Q2 2020 | $3,524,000 | -8.4% | 73,462 | -12.2% | 0.00% | 0.0% |
Q1 2020 | $3,848,000 | -24.0% | 83,644 | -0.7% | 0.00% | 0.0% |
Q4 2019 | $5,063,000 | -25.7% | 84,258 | -30.0% | 0.00% | 0.0% |
Q3 2019 | $6,811,000 | +27.8% | 120,369 | +25.7% | 0.00% | 0.0% |
Q2 2019 | $5,331,000 | -21.9% | 95,728 | -29.2% | 0.00% | 0.0% |
Q1 2019 | $6,822,000 | +122.8% | 135,122 | +77.7% | 0.00% | 0.0% |
Q4 2018 | $3,062,000 | -16.5% | 76,030 | +43.7% | 0.00% | 0.0% |
Q3 2018 | $3,667,000 | -31.6% | 52,909 | -25.3% | 0.00% | 0.0% |
Q2 2018 | $5,360,000 | +307.0% | 70,833 | +183.6% | 0.00% | – |
Q1 2018 | $1,317,000 | -15.7% | 24,976 | -14.7% | 0.00% | – |
Q4 2017 | $1,563,000 | -32.4% | 29,269 | -24.5% | 0.00% | – |
Q3 2017 | $2,313,000 | +44.0% | 38,785 | +90.5% | 0.00% | – |
Q2 2017 | $1,606,000 | +31.1% | 20,356 | +37.9% | 0.00% | – |
Q1 2017 | $1,225,000 | +7.0% | 14,765 | +2.3% | 0.00% | – |
Q4 2016 | $1,145,000 | +913.3% | 14,431 | +789.2% | 0.00% | – |
Q3 2016 | $113,000 | -1.7% | 1,623 | -45.0% | 0.00% | – |
Q2 2016 | $115,000 | -94.6% | 2,951 | -94.4% | 0.00% | -100.0% |
Q1 2016 | $2,143,000 | +173.7% | 52,924 | +499.9% | 0.00% | – |
Q4 2015 | $783,000 | +1566.0% | 8,822 | +1278.4% | 0.00% | – |
Q3 2015 | $47,000 | -92.5% | 640 | -91.8% | 0.00% | – |
Q2 2015 | $629,000 | +263.6% | 7,778 | -35.6% | 0.00% | – |
Q2 2014 | $173,000 | – | 12,076 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |